Can ulcerative colitis cause hot flashes, weight loss, hypertriglyceridemia, and elevated γ‑glutamyl transferase (GGT)?

Ulcerative Colitis and Atypical Systemic Manifestations

Ulcerative colitis does not typically cause hot flashes, but can cause weight loss; abnormal triglycerides and elevated GGT are not classic UC manifestations but may indicate disease severity or associated hepatobiliary complications, particularly primary sclerosing cholangitis.

Weight Loss in Ulcerative Colitis

Weight loss is a recognized manifestation of active ulcerative colitis, particularly during disease flares 1. This occurs through:

• Active inflammation driving increased metabolic demands and nutrient malabsorption 1
• Reduced oral intake due to abdominal pain, diarrhea, and fear of symptom exacerbation 1
• Protein-losing enteropathy in severe disease 1

Weight loss severity correlates with disease activity and should prompt evaluation for active inflammation using fecal calprotectin >150 mg/g, elevated fecal lactoferrin, or elevated CRP 2.

Hot Flashes and Ulcerative Colitis

Hot flashes are not a recognized manifestation of ulcerative colitis in any major guideline 2, 3, 4, 5. The typical presenting symptoms of UC include bloody diarrhea, abdominal pain, fecal urgency, and tenesmus 1.

If hot flashes are present, investigate alternative etiologies including:

• Medication side effects (particularly corticosteroids causing vasomotor symptoms)
• Thyroid dysfunction (which can coexist with autoimmune conditions)
• Menopausal status in women
• Other systemic conditions unrelated to UC

Elevated Triglycerides in Ulcerative Colitis

Hypertriglyceridemia is actually more common in UC patients compared to the general population and paradoxically correlates with disease severity 6. Key findings include:

• UC patients have more frequent high triglycerides (33% vs. 25% in general population, p<0.001) 6
• High triglyceride levels are independently associated with more severe disease, including increased IBD surgeries 6
• Median triglycerides are lower in UC compared to Crohn's disease (100 vs. 123 mg/dL, p<0.001), but still elevated compared to healthy controls 6

This represents a marker of disease severity and systemic inflammation rather than a direct UC manifestation 6. The dyslipidemia pattern in IBD (low HDL, high triglycerides, low total cholesterol) reflects chronic inflammation and may contribute to increased cardiovascular risk 6.

Elevated GGT in Ulcerative Colitis

Elevated gamma-glutamyl transferase (GGT) in UC patients warrants immediate evaluation for hepatobiliary complications, particularly primary sclerosing cholangitis (PSC) 7, 8.

Critical Associations:

• Elevated GGT at UC diagnosis strongly predicts PSC development: 72.7% of children with high baseline GGT developed PSC-UC versus only 1.2% with normal GGT (p<0.001) 7
• Combined elevation of both ALT and GGT >50 IU/L within 90 days of IBD diagnosis is associated with a 50% likelihood of IBD-associated liver disease (odds ratio 660, p<0.0001) 8
• PSC-UC is more common in ulcerative colitis (4%) than Crohn's disease (0.8%, p<0.001) 8

Recommended Evaluation:

When GGT is elevated in a UC patient, immediately:

• Measure both ALT and GGT (not GGT alone) to assess hepatobiliary disease risk 8
• Exclude infectious causes (Clostridioides difficile and other enteric pathogens) as these can elevate inflammatory markers including liver enzymes 2, 9
• Perform magnetic resonance cholangiopancreatography (MRCP) if both ALT and GGT are elevated to evaluate for PSC 7, 8
• Check perinuclear antineutrophil cytoplasmic antibodies (p-ANCA), as 90.9% of UC patients with high GGT are p-ANCA positive 7

Clinical Pitfall:

Do not attribute isolated GGT elevation to UC disease activity alone—this requires hepatobiliary investigation 7, 8. PSC significantly increases colorectal cancer surveillance requirements and alters long-term prognosis 3, 4.

Integrated Clinical Approach

When a UC patient presents with weight loss, abnormal triglycerides, and elevated GGT:

1. Assess UC disease activity using fecal calprotectin >150 mg/g, elevated fecal lactoferrin, or elevated CRP combined with symptoms 2
2. Measure both ALT and GGT to stratify hepatobiliary disease risk 8
3. If both ALT and GGT >50 IU/L, proceed with MRCP to evaluate for PSC 7, 8
4. Recognize that high triglycerides and low cholesterol indicate more severe UC requiring potential treatment escalation 6
5. Investigate hot flashes as a separate entity unrelated to UC 3, 4, 1, 5

The combination of weight loss and abnormal lipids suggests active, potentially severe UC, while elevated GGT raises concern for PSC—a distinct complication requiring specific surveillance and management 7, 8, 6.